新药与医疗器械获批前比较证据的生成
欧美新药获批时不足半数具备与现有治疗方案的比较获益和危害数据,医疗器械比较证据更少。文章提出五项关键原则,涉及标签、监管审批项目、随机对照试验、网络荟萃分析和支付方激励,以促进药品和器械公司生成比较数据并确保决策所需证据及时可用。
要点
- 新药获批时比较证据普遍不足,医疗器械更甚。
- 五项原则涵盖标签告知、监管选择性、活性对照试验、前瞻性网络荟萃分析和支付激励。
- 支付方可通过定价和支付决策考量已证实的附加获益来激励比较证据生成。
核心结论
- 欧美新药获批时不足半数具备与现有治疗方案的比较获益和危害数据,医疗器械比较证据更少。
- 提出五项关键原则为药品和器械公司生成比较数据提供激励,并确保决策所需证据及时可用。
主要发现
- 欧洲和美国新药监管批准时,不足半数具有与现有治疗方案的比较获益和危害数据。
- 即使存在活性对照试验,也可能无法产生对临床实践和卫生政策决策有意义的数据。
- 医疗器械的比较证据生成比药品更稀疏。
关键数值与推荐
- 原则一:标签应常规告知患者和临床医生新产品是否存在比较数据。
- 原则二:监管机构应更有选择性地使用基于不完整获益和危害数据加速药品和器械批准的項目。
- 原则三:监管机构应鼓励开展以活性对照为对照的随机试验。
- 原则四:监管机构应使用基于现有和未来随机试验的前瞻性设计网络荟萃分析。
- 原则五:支付方应利用政策杠杆和谈判权力激励新药和现有药品及器械比较证据的生成,例如在定价和支付决策中明确考虑已证实的附加获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the USA. Even when active-comparator trials exist, they might not produce meaningful data to inform decisions in clinical practice and health policy. The uncertainty associated with the paucity of well designed active-comparator trials has been compounded by legal and regulatory changes in Europe and the USA that have created a complex mix of expedited programmes aimed at facilitating faster access to new drugs. Comparative evidence generation is even sparser for medical devices. Some have argued that the current process for regulatory approval needs to generate more evidence that is useful for patients, clinicians, and payers in health-care systems. We propose a set of five key principles relevant to the European Medicines Agency, European medical device regulatory agencies, US Food and Drug Administration, as well as payers, that we believe will provide the necessary incentives for pharmaceutical and device companies to generate comparative data on drugs and devices and assure timely availability of evidence that is useful for decision making. First, labelling should routinely inform patients and clinicians whether comparative data exist on new products. Second, regulators should be more selective in their use of programmes that facilitate drug and device approvals on the basis of incomplete benefit and harm data. Third, regulators should encourage the conduct of randomised trials with active comparators. Fourth, regulators should use prospectively designed network meta-analyses based on existing and future randomised trials. Last, payers should use their policy levers and negotiating power to incentivise the generation of comparative evidence on new and existing drugs and devices, for example, by explicitly considering proven added benefit in pricing and payment decisions.
引用
- Naci H, Salcher-Konrad M, Kesselheim AS, et al. Generating comparative evidence on new drugs and devices before approval. Lancet. 2020. PMID: 32199486. doi:10.1016/S0140-6736(19)33178-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。